Meta-analysis of the efficacy of recombinant human growth hormone and human serum albumin in the treatment of liver cirrhosis with hypoproteinemia
10.3760/cma.j.issn.1008-6706.2020.23.003
- VernacularTitle:重组人生长激素与人血白蛋白治疗肝硬化低蛋白血症疗效的Meta分析
- Author:
Yaochang GUO
1
;
Changming JIANG
;
Wenlin SHU
Author Information
1. 北京中医药大学厦门医院药学部 361009
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(23):2825-2829
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy, safety and economy of recombinant human growth hormone (rhGH) in the treatment of patients with liver cirrhosis and hypoproteinemia.Methods:Computer search for randomized controlled trials included in Chinese Biomedical Literature Database(CBM), Wanfang Medicine, Weipu Medicine, Embase, PubMed, Cochrane Library and other databases from January 1, 2000 to January 1, 2019, and excluded according to certain criteria.RevMan5.3 software was used for statistical analysis.Results:A total of 13 articles were included in the meta-analysis, a total of 739 patients.The results showed that the short-term efficacy of rhGH in the treatment of cirrhosis with hypoproteinemia had no statistically significant difference compared with human serum albumin (HSA)[WMD=-0.42, 95% CI(-1.77, 0.92), P=0.54], but the mid-and long-term effects of rhGH were better[WMD=3.42, 95% CI(0.13, 6.70), P=0.04; WMD=7.12, 95% CI(4.75, 9.50), P<0.001]. Conclusion:The application of rhGH in the treatment of cirrhosis with hypoproteinemia is equivalent to the infusion of HSA in short-term efficacy, but the duration of treatment is prolonged, has no obvious adverse reactions, and is more economical.
